Indaptus Therapeutics entered into warrant repricing agreements on February 11, 2026, reducing the exercise price of certain warrants to $1.75 per share and securing voting commitments from holders for an upcoming special stockholder meeting. This action adjusts existing financing terms and aligns shareholder votes on key proposals.
Key takeaways
Company entered into warrant repricing agreements on February 11, 2026, reducing exercise prices to $1.75 per share.
913,638 shares of common stock warrants held by Executing Holders were repriced through agreements.
Executing Holders agreed to vote all common stock shares in favor of proposals at the February 26, 2026 special meeting.
Board unilaterally reduced exercise prices for an additional 762,787 shares of warrants to $1.75 per share.
Original warrant exercise prices ranged from $8.30 to $47.60 per share before repricing.
Warrants were originally issued in financing rounds during 2024 and 2025.